Second Annual Workshop on Clinical Outcome Assessments in Cancer Clinical Trials; Public Workshop, 18303-18304 [2017-07766]
Download as PDF
18303
Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices
Requests for Oral Comments: During
online registration you may indicate if
you wish to provide a statement during
the Open Public Comment Period. We
will do our best to accommodate
requests to make public comments
based on time allocated for public
comment. Individuals and organizations
with common interests are urged to
consolidate or coordinate their
comments, and request time for a joint
presentation. Following the close of
registration date, we will determine the
amount of time allotted to each
commenter and the approximate time
each oral comment is scheduled to
begin; commenters should arrive ahead
of their scheduled time in case the
agenda moves ahead of schedule so as
to be sure not to forfeit their speaking
time. All requests to make oral
comments must be received by the close
of registration on May 1, 2017. No
commercial or promotional material
will be permitted to be presented or
distributed at the public workshop.
Streaming Webcast of the Public
Workshop: This public workshop will
also be Webcast. Additional information
will be made available regarding
accessing the Webcast 2 days prior to
the public workshop at https://
www.fda.gov/Drugs/NewsEvents/
ucm538047.htm.
Transcripts: Please be advised that as
soon as a transcript of the public
workshop is available, it will be
accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(see ADDRESSES). A link to the
transcript will also be available on the
Internet at https://www.fda.gov/Drugs/
NewsEvents/ucm538047.htm.
Dated: April 13, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–07821 Filed 4–17–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
sradovich on DSK3GMQ082PROD with NOTICES
[Docket No. FDA–2017–N–1989]
Second Annual Workshop on Clinical
Outcome Assessments in Cancer
Clinical Trials; Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration’s (FDA’s) Center for
Drug Evaluation and Research, in co-
SUMMARY:
VerDate Sep<11>2014
16:55 Apr 17, 2017
Jkt 241001
sponsorship with the Critical Path
Institute’s (C-Path) Patient-Reported
Outcome (PRO) Consortium, is
announcing a public workshop entitled
‘‘Second Annual Workshop on Clinical
Outcome Assessments in Cancer
Clinical Trials.’’ The purpose of the
public workshop is to provide a forum
for collaborative multidisciplinary
discussion to identify opportunities and
address challenges for clinical outcome
assessments, particularly patientreported outcome (PRO) assessments, in
oncology drug development. In this
public workshop, a broad array of
international stakeholders involved in
oncology drug development and PRO
measurement will provide perspectives
on the role of PRO measures to provide
complementary clinical data on the
symptomatic side effects of anti-cancer
agents. Speakers and panelists will
explore the utility of information
derived from existing and emerging PRO
measures and discuss potential ways to
improve the collection, analysis, and
presentation of the data to support drug
development and better inform
treatment decisions. In addition,
workshop participants will discuss
possible approaches to the patientreported assessment of an
investigational drug’s overall side effect
burden as a clinical trial endpoint. This
public workshop will include speakers
and panelists from regulatory agencies,
academia, patient advocacy groups, and
the medical product industry.
DATES: The public workshop will be
held on April 25, 2017, from 8 a.m. to
5 p.m. See the SUPPLEMENTARY
INFORMATION section for registration date
and information.
ADDRESSES: The public workshop will
be held at the Hyatt Regency Bethesda,
One Bethesda Metro Center, 7400
Wisconsin Ave., Bethesda, MD 20814,
301–657–1234.
FOR FURTHER INFORMATION CONTACT:
Theresa Hall, Patient-Reported Outcome
Consortium, Critical Path Institute, 1730
East River Road, Tucson, AZ 85718,
520–777–2875, FAX: 525–547–3456,
email: thall@c-path.org; and Valerie
Vashio, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993, 301–
796–3710, FAX: 301–796–9909, email:
valerie.vashio@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Clinical outcome assessment (COA)
tools are intended to capture how
patients experience a disease and its
treatment by assessing symptoms,
function, and other aspects of a patient’s
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
health-related quality of life (HRQL).
PRO measures are one important type of
COA tool. There is growing interest in
optimizing the use of PRO measures to
better incorporate the patient
perspective into oncology drug
development. While PRO measures can
be used to evaluate the efficacy of
cancer treatments, there is increasing
interest in the use of PRO tools to assess
symptomatic side effects of treatment.
New PRO item banks and libraries are
becoming available that can provide
needed flexibility to tailor the PRO
assessment to the wide range of side
effects seen with the various
mechanistic classes utilized in
contemporary drug development. FDA
is interested in gaining feedback on
methods to integrate the patient into the
assessment of safety and tolerability of
cancer drugs through systematic patientreporting of side effects during clinical
trials. This public workshop will
discuss standard clinician reporting of
adverse events, the development and
implementation of the PRO-Common
Terminology Criteria for Adverse Events
(CTCAE) assessment tool, and explore
different analysis and presentation
methods for longitudinal patientreported adverse event data.
II. Registration and Accommodations
A. Registration
There is a registration fee to attend
this public workshop. The registration
fee is charged to help defray the costs
of the public workshop facility, speaker
and panelist expenses, audiovisual
equipment, materials, and food. Persons
interested in attending this public
workshop must register by April 21,
2017. If time and space permit, onsite
registration on the day of the public
workshop will be provided beginning at
8 a.m. Seats are limited, and registration
will be on a first-come, first-served
basis.
To register for the public workshop,
please complete registration online at
https://www.cvent.com/events/secondannual-workshop-on-clinical-outcomeassessments-coas-in-cancer-clinicaltrials/registration-270d8a5ee3ae4a
108938851e2a7d0ea7.aspx. (FDA has
verified the Web site addresses, as of the
date this document publishes in the
Federal Register, but Web sites are
subject to change over time.) The costs
of registration for the different
categories of attendees are as follows:
Category
Industry Representatives.
Charitable Nonprofit/
Academic.
E:\FR\FM\18APN1.SGM
18APN1
Cost
$400.
$100 (Contact CPath).
18304
Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices
Category
Government ..............
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Cost
$100 (Contact CPath).
Office of the Secretary
B. Accommodations
[Document Identifier: 0937–0198–30D]
Attendees are responsible for their
own hotel accommodations. Attendees
making reservations at the Hyatt
Regency Bethesda, One Bethesda Metro
Center, Bethesda, MD 20814, are eligible
for a reduced rate of $249 per night, not
including applicable taxes. To receive
the reduced rate, please contact the
hotel directly at 301–657–1234 and
reference the Critical Path Institute
April 2017 workshop or book online at:
https://aws.passkey.com/event/
15624700/owner/14877/landing?
gtid=8d00149fbdf860c0e824aee
45de33531.
If you need special accommodations
due to a disability, please contact the
Hyatt Regency Bethesda at least 7 days
in advance.
Agency Information Collection
Activities; Submission to OMB for
Review and Approval; Public Comment
Request
III. Transcripts
Transcripts will not be available.
Presentations and associated audio files
will be available on the C-Path Web site
approximately 30 days after the public
workshop at https://c-path.org/category/
events/.
Dated: April 12, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–07766 Filed 4–17–17; 8:45 am]
BILLING CODE 4164–01–P
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
In compliance with the
Paperwork Reduction Act of 1995, the
Office of the Secretary (OS), Department
of Health and Human Services, has
submitted an Information Collection
Request (ICR), described below, to the
Office of Management and Budget
(OMB) for review and approval. The ICR
is for renewal of the approved
information collection assigned OMB
control number , scheduled to
expire on . Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public on this ICR during the review
and approval period.
DATES: Comments on the ICR must be
received on or before May 18, 2017.
ADDRESSES: Submit your comments to
OIRA_submission@omb.eop.gov or via
facsimile to (202) 395–5806.
FOR FURTHER INFORMATION CONTACT:
Information Collection Clearance staff,
Information.CollectionClearance@
hhs.gov or (202) 795–7714.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the OMB
control number 0937–0198 and
document identifier 0937–0198–30D for
reference.
Information Collection Request Title:
Public Health Service Polices on
Research Misconduct (42 CFR part 93)—
SUMMARY:
OMB No. 0937–0198—Extension—
Office of Resource Integrity.
OMB No.: 0937–0198.
Abstract: This is a request to extend
the currently approved collection, OMB
No. 0937–0198, which involves two
forms: PHS–6349 and PHS–6315. The
purpose of the Institutional Assurance
and Annual Report on Possible Research
Misconduct form (PHS–6349) is to
provide data on the amount of research
misconduct activity occurring in
institutions conducting PHS-supported
research, as well as providing an annual
assurance that those institutions have
established and will follow
administrative policies and procedures
for responding to allegations of research
misconduct that comply with the Public
Health Service (PHS) Regulations on
Research Misconduct (42 CFR part 93).
The purpose of the Assurance of
Compliance by Sub-Award Recipients
form (PHS–6315) is to establish a
similar assurance of compliance with 42
CFR part 93 for sub-awardee
institutions, as well as provide data on
the amount of research misconduct
activity occurring in those sub-awardee
institutions. Research misconduct is
defined as receipt of an allegation of
research misconduct and/or the conduct
of an inquiry and/or investigation into
such allegations. These data enable the
ORI to monitor institutional compliance
with the PHS regulation. Lastly, the
forms will be used to respond to
congressional requests for information
to prevent misuse of Federal funds and
to protect the public interest.
Need and Proposed Use of the
Information: Public Health Service
Polices on Research Misconduct (42
CFR part 93)—OMB No. 0937–0198—
Extension—Office of Research Integrity.
Likely Respondents: PHS awardee and
sub-awardee institutions.
The total annual burden hours
estimated for this ICR are summarized
in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
hours
sradovich on DSK3GMQ082PROD with NOTICES
PHS–6349 ........................................................................................................
PHS–6315 ........................................................................................................
5,435
200
1
1
10/60
5/60
906
17
Total ..........................................................................................................
........................
........................
........................
923
Terry S. Clark,
Asst Information Collection Clearance
Officer.
[FR Doc. 2017–07787 Filed 4–17–17; 8:45 am]
BILLING CODE 4150–31–P
VerDate Sep<11>2014
16:55 Apr 17, 2017
Jkt 241001
PO 00000
Frm 00028
Fmt 4703
Sfmt 9990
E:\FR\FM\18APN1.SGM
18APN1
Agencies
[Federal Register Volume 82, Number 73 (Tuesday, April 18, 2017)]
[Notices]
[Pages 18303-18304]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07766]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-1989]
Second Annual Workshop on Clinical Outcome Assessments in Cancer
Clinical Trials; Public Workshop
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration's (FDA's) Center for Drug
Evaluation and Research, in co-sponsorship with the Critical Path
Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium, is
announcing a public workshop entitled ``Second Annual Workshop on
Clinical Outcome Assessments in Cancer Clinical Trials.'' The purpose
of the public workshop is to provide a forum for collaborative
multidisciplinary discussion to identify opportunities and address
challenges for clinical outcome assessments, particularly patient-
reported outcome (PRO) assessments, in oncology drug development. In
this public workshop, a broad array of international stakeholders
involved in oncology drug development and PRO measurement will provide
perspectives on the role of PRO measures to provide complementary
clinical data on the symptomatic side effects of anti-cancer agents.
Speakers and panelists will explore the utility of information derived
from existing and emerging PRO measures and discuss potential ways to
improve the collection, analysis, and presentation of the data to
support drug development and better inform treatment decisions. In
addition, workshop participants will discuss possible approaches to the
patient-reported assessment of an investigational drug's overall side
effect burden as a clinical trial endpoint. This public workshop will
include speakers and panelists from regulatory agencies, academia,
patient advocacy groups, and the medical product industry.
DATES: The public workshop will be held on April 25, 2017, from 8 a.m.
to 5 p.m. See the SUPPLEMENTARY INFORMATION section for registration
date and information.
ADDRESSES: The public workshop will be held at the Hyatt Regency
Bethesda, One Bethesda Metro Center, 7400 Wisconsin Ave., Bethesda, MD
20814, 301-657-1234.
FOR FURTHER INFORMATION CONTACT: Theresa Hall, Patient-Reported Outcome
Consortium, Critical Path Institute, 1730 East River Road, Tucson, AZ
85718, 520-777-2875, FAX: 525-547-3456, email: path.org">thall@c-path.org; and
Valerie Vashio, Center for Drug Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-
796-3710, FAX: 301-796-9909, email: valerie.vashio@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Clinical outcome assessment (COA) tools are intended to capture how
patients experience a disease and its treatment by assessing symptoms,
function, and other aspects of a patient's health-related quality of
life (HRQL). PRO measures are one important type of COA tool. There is
growing interest in optimizing the use of PRO measures to better
incorporate the patient perspective into oncology drug development.
While PRO measures can be used to evaluate the efficacy of cancer
treatments, there is increasing interest in the use of PRO tools to
assess symptomatic side effects of treatment. New PRO item banks and
libraries are becoming available that can provide needed flexibility to
tailor the PRO assessment to the wide range of side effects seen with
the various mechanistic classes utilized in contemporary drug
development. FDA is interested in gaining feedback on methods to
integrate the patient into the assessment of safety and tolerability of
cancer drugs through systematic patient-reporting of side effects
during clinical trials. This public workshop will discuss standard
clinician reporting of adverse events, the development and
implementation of the PRO-Common Terminology Criteria for Adverse
Events (CTCAE) assessment tool, and explore different analysis and
presentation methods for longitudinal patient-reported adverse event
data.
II. Registration and Accommodations
A. Registration
There is a registration fee to attend this public workshop. The
registration fee is charged to help defray the costs of the public
workshop facility, speaker and panelist expenses, audiovisual
equipment, materials, and food. Persons interested in attending this
public workshop must register by April 21, 2017. If time and space
permit, onsite registration on the day of the public workshop will be
provided beginning at 8 a.m. Seats are limited, and registration will
be on a first-come, first-served basis.
To register for the public workshop, please complete registration
online at https://www.cvent.com/events/second-annual-workshop-on-clinical-outcome-assessments-coas-in-cancer-clinical-trials/registration-270d8a5ee3ae4a108938851e2a7d0ea7.aspx. (FDA has verified
the Web site addresses, as of the date this document publishes in the
Federal Register, but Web sites are subject to change over time.) The
costs of registration for the different categories of attendees are as
follows:
------------------------------------------------------------------------
Category Cost
------------------------------------------------------------------------
Industry Representatives.................. $400.
Charitable Nonprofit/Academic............. $100 (Contact C-Path).
[[Page 18304]]
Government................................ $100 (Contact C-Path).
------------------------------------------------------------------------
B. Accommodations
Attendees are responsible for their own hotel accommodations.
Attendees making reservations at the Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814, are eligible for a reduced
rate of $249 per night, not including applicable taxes. To receive the
reduced rate, please contact the hotel directly at 301-657-1234 and
reference the Critical Path Institute April 2017 workshop or book
online at: https://aws.passkey.com/event/15624700/owner/14877/landing?gtid=8d00149fbdf860c0e824aee45de33531.
If you need special accommodations due to a disability, please
contact the Hyatt Regency Bethesda at least 7 days in advance.
III. Transcripts
Transcripts will not be available. Presentations and associated
audio files will be available on the C-Path Web site approximately 30
days after the public workshop at https://c-path.org/category/events/.
Dated: April 12, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-07766 Filed 4-17-17; 8:45 am]
BILLING CODE 4164-01-P